

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

MCA-205

RRID:CVCL_VR90

Type: Cell Line

Proper Citation

RRID:CVCL_VR90

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_VR90

Proper Citation: RRID:CVCL_VR90

Description: Cell line MCA-205 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Disease: Mouse fibrosarcoma

Comments: Characteristics: Excellent model for studying the immune responses to tumor cells and for supporting the development of targeted cancer immunotherapies (Millipore=SCC173).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: MCA-205

Synonyms: MCA 205, MCA205

Cross References: Lonza:1177, Millipore:SCC173, Wikidata:Q95985779

ID: CVCL_VR90

Record Creation Time: 20220427T220749+0000

Record Last Update: 20260829T234551+0000

Ratings and Alerts

No rating or validation information has been found for MCA-205.

No alerts have been found for MCA-205.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Fu R, et al. (2026) Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. bioRxiv : the preprint server for biology.

Islam R, et al. (2025) TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis. Molecular oncology, 19(8), 2431.

Alicea Pauneto CDM, et al. (2025) Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity.

Allard D, et al. (2025) Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis. Cancer research, 85(4), 692.

Holay N, et al. (2025) INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering. Journal for immunotherapy of cancer, 13(5).

Hunt EG, et al. (2024) Acetyl-CoA carboxylase obstructs CD8+ T cell lipid utilization in the tumor microenvironment. Cell metabolism.

Wu J, et al. (2024) A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R β strengthens T cell-mediated anti-tumor therapies. Cell reports. Medicine, 5(10), 101747.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity, 57(7), 1514.

Knorr DA, et al. (2024) Fc γ RIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research, 12(3), 322.

Charalambous A, et al. (2024) Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas. Molecular cancer therapeutics, 23(11), 1555.

Montégut L, et al. (2024) Acyl-coenzyme A binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. Molecular cancer, 23(1), 187.

Riesenberg BP, et al. (2022) Stress-Mediated Attenuation of Translation Undermines T-cell Activity in Cancer. *Cancer research*, 82(23), 4386.

Zhao L, et al. (2022) Interference of immunogenic chemotherapy by artificially controlled calreticulin secretion from tumor cells. *Methods in cell biology*, 172, 99.

Zhao L, et al. (2021) A genotype-phenotype screening system using conditionally immortalized immature dendritic cells. *STAR protocols*, 2(3), 100732.